Additional Opportunities

We’re investigating a portfolio of additional ASOs aimed to treating additional CF mutations as well as pulmonary diseases, which can be properly addressed and treated  by splicing modulation.  We are utilizing our established algorithm, screening technics, proprietary technology and internal well established bio-assays for ASOs lead selection and optimization. Those program are in early/late discovery phase.
Scroll Up Skip to content